These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 25738452)
1. FFAR out new targets for diabetes. Prentice KJ; Wheeler MB Cell Metab; 2015 Mar; 21(3):353-4. PubMed ID: 25738452 [TBL] [Abstract][Full Text] [Related]
2. Loss of FFA2 and FFA3 increases insulin secretion and improves glucose tolerance in type 2 diabetes. Tang C; Ahmed K; Gille A; Lu S; Gröne HJ; Tunaru S; Offermanns S Nat Med; 2015 Feb; 21(2):173-7. PubMed ID: 25581519 [TBL] [Abstract][Full Text] [Related]
5. FFA2-, but not FFA3-agonists inhibit GSIS of human pseudoislets: a comparative study with mouse islets and rat INS-1E cells. Lorza-Gil E; Kaiser G; Rexen Ulven E; König GM; Gerst F; Oquendo MB; Birkenfeld AL; Häring HU; Kostenis E; Ulven T; Ullrich S Sci Rep; 2020 Oct; 10(1):16497. PubMed ID: 33020504 [TBL] [Abstract][Full Text] [Related]
6. Free fatty acid receptor 1 as a novel therapeutic target for type 2 diabetes mellitus-current status. Eleazu C; Charles A; Eleazu K; Achi N Chem Biol Interact; 2018 Jun; 289():32-39. PubMed ID: 29704509 [TBL] [Abstract][Full Text] [Related]
7. Gut Microbiota: FFAR Reaching Effects on Islets. Priyadarshini M; Navarro G; Layden BT Endocrinology; 2018 Jun; 159(6):2495-2505. PubMed ID: 29846565 [TBL] [Abstract][Full Text] [Related]
8. Sweet taste receptors regulate basal insulin secretion and contribute to compensatory insulin hypersecretion during the development of diabetes in male mice. Kyriazis GA; Smith KR; Tyrberg B; Hussain T; Pratley RE Endocrinology; 2014 Jun; 155(6):2112-21. PubMed ID: 24712876 [TBL] [Abstract][Full Text] [Related]
9. Modulating GPR40: therapeutic promise and potential in diabetes. Poitout V; Lin DC Drug Discov Today; 2013 Dec; 18(23-24):1301-8. PubMed ID: 24051395 [TBL] [Abstract][Full Text] [Related]
10. Investigational insulin secretagogues for type 2 diabetes. Scheen AJ Expert Opin Investig Drugs; 2016; 25(4):405-22. PubMed ID: 26881467 [TBL] [Abstract][Full Text] [Related]
11. The pancreatic beta-cell in human Type 2 diabetes. Marchetti P; Del Prato S; Lupi R; Del Guerra S Nutr Metab Cardiovasc Dis; 2006 Mar; 16 Suppl 1():S3-6. PubMed ID: 16530127 [TBL] [Abstract][Full Text] [Related]
12. [Comeback for the beta cells in the pathogenesis of diabetes]. Mulder H Lakartidningen; 2010 Nov 10-16; 107(45):2796-800. PubMed ID: 21179864 [No Abstract] [Full Text] [Related]
13. Anti-diabetic action of all-trans retinoic acid and the orphan G protein coupled receptor GPRC5C in pancreatic β-cells. Amisten S; Mohammad Al-Amily I; Soni A; Hawkes R; Atanes P; Persaud SJ; Rorsman P; Salehi A Endocr J; 2017 Mar; 64(3):325-338. PubMed ID: 28228611 [TBL] [Abstract][Full Text] [Related]
14. The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function. Yoshida S; Ohishi T; Matsui T; Tanaka H; Oshima H; Yonetoku Y; Shibasaki M Diabetes Obes Metab; 2011 Jan; 13(1):34-41. PubMed ID: 21114601 [TBL] [Abstract][Full Text] [Related]
16. TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. Tsujihata Y; Ito R; Suzuki M; Harada A; Negoro N; Yasuma T; Momose Y; Takeuchi K J Pharmacol Exp Ther; 2011 Oct; 339(1):228-37. PubMed ID: 21752941 [TBL] [Abstract][Full Text] [Related]
17. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes. Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289 [TBL] [Abstract][Full Text] [Related]
18. BuMP-ing up insulin secretion by pancreatic beta cells. Gannon M Cell Metab; 2007 Mar; 5(3):157-9. PubMed ID: 17339021 [TBL] [Abstract][Full Text] [Related]
19. Association of hematological parameters with insulin resistance and beta-cell dysfunction in nondiabetic subjects. Hanley AJ; Retnakaran R; Qi Y; Gerstein HC; Perkins B; Raboud J; Harris SB; Zinman B J Clin Endocrinol Metab; 2009 Oct; 94(10):3824-32. PubMed ID: 19622625 [TBL] [Abstract][Full Text] [Related]
20. Insulin response in relation to insulin sensitivity: an appropriate beta-cell response in black South African women: response to Goedecke et al. Joffe BI; Distiller LA Diabetes Care; 2009 Oct; 32(10):e123; author reply e124. PubMed ID: 19793997 [No Abstract] [Full Text] [Related] [Next] [New Search]